This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
by Zacks Equity Research
Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
Here's Why You Should Retain Ecolab (ECL) Stock Right Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness remains a woe.
Fresenius Medical's (FMS) Training Center to Boost Patient Care
by Zacks Equity Research
Fresenius Medical (FMS) inaugurates new training center in Korea to help in the improvement of patient care by offering comprehensive education programs for healthcare professionals.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
by Zacks Equity Research
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
Moving Average Crossover Alert: Veeva Systems (VEEV)
by Zacks Equity Research
Veeva Systems (VEEV) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research
by Zacks Equity Research
Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.
BD's (BDX) PeritX System Gets FDA's Expanded 510(k) Clearance
by Zacks Equity Research
BD's (BDX) receipt of the expanded FDA indication for its PeritX System is expected to lessen the number of hospital trips a patient takes for fluid removal.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises a concern.
Patterson Companies (PDCO) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2021 results benefit from strong segmental performance.
PerkinElmer (PKI) to Boost Portfolio via SIRION Acquisition
by Zacks Equity Research
PerkinElmer (PKI) expects to be able to support its cell and gene therapy workflows, and expand its existing research solutions via the latest buyout.
AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.
Masimo's (MASI) Wearable Wireless Thermometer Gets FDA Nod
by Zacks Equity Research
Masimo's (MASI) continuous, wearable thermometer is likely to help monitor and track body temperature in all thermometer applications following the FDA's clearance.
NextGen (NXGN) Partners With Palmetto to Boost Patient Experience
by Zacks Equity Research
NextGen (NXGN) collaborates with Palmetto to enhance patient experience, through the latter's adoption of NextGen RCM Services.
OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility
by Zacks Equity Research
OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at Dental segment.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.
Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch
by Trina Mukherjee
Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.
AMN Healthcare (AMN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AMN Healthcare (AMN) is optimistic about maintaining its strength in staffing service as well as offering a broad array of services.
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
by Zacks Equity Research
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.